Stocks · News reference
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
IN8bio (NASDAQ:INAB) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.37) by 32.43 percent. This is a 79.84 percent increase over losses of $(1.24) per share from the same
Read original at benzingaGainers Tenet Healthcare (NYSE:THC) shares rose 14.1% to $227.06 during Thursday's after-market session. The company's market cap stands at $17.1 billion. As per the news, the Q2 earnings report came out today.
Read original at benzingaIN8bio announced peer-reviewed clinical results from its Phase 1 trial of INB-200 (DeltEx DRI) published in The Journal of Clinical Oncology. The chemotherapy-resistant gamma-delta T cell therapy demonstrated a median progression-free survival of 16.1 months in repeat-dose patients, more than double the standard of care benchmark of 6.9 months, with no dose-limiting toxicities. The therapy showed a well-tolerated safety profile and median overall survival of 19.5 months in repeat-dose patients.
Read original at globenewswire-inc